Treatment Action Group (TAG) welcomes the report published today by the World Health Organization TB Vaccine Accelerator Council on how to finance global, equitable access to new TB vaccines.
TAG and the Community Research Advisors Group (CRAG) are happy to introduce the TB Representative Studies Rubric (TB RSR), a new tool that community advisory boards (CABs) can use when designing and reviewing clinical trials protocols. The TB RSR is a 17-item questionnaire that assesses whether TB treatment trials include the types of people who get TB.
Treatment Action Group (TAG) opposes in the strongest possible terms the suspension of at least 22 TB research awards by the National Institutes of Health (NIH) following a May 2025 White House executive order banning “gain-of-function” research.
The World Health Organization (WHO) guidelines for diagnosing TB have evolved along with available technologies and tools that are increasingly accurate, simple, and efficient at detecting TB and resistance to a wider range of TB drugs.
I’m proud to share with you TAG’s 2024 Annual Report. Last year already seems long ago with all the attacks on research and health care, domestic and international, which are currently taking place under the new administration...
On June 5, 2025, TAG and WHO cohosted a webinar orienting people to long-acting injectables for TB treatment and prevention. Long-acting Injectables (LAIs) have the potential to revolutionize treatment for TB and other infectious diseases.
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 3rd meeting of the WHO Director-General’s TB Vaccine Accelerator Council on May 20, 2025 in Geneva, Switzerland.
Lifesaving scientific research on prevention, testing, treatment and care for people living with HIV and tuberculosis (TB) in South Africa is under serious threat due to funding suspensions and grant terminations from the United States (US) government.
Developed by TAG, Médecins Sans Frontières, and the South African Medical Research Council, this issue brief provides information about TB and HIV clinical trials and research programs impacted by U.S. government funding disruptions...
This webinar will provide a platform to learn about the findings from the Longevity HCV and TB end users and healthcare providers/policy makers surveys, and for community members, especially marginalized populations across the world, to engage with the researchers developing these Long-Acting Therapies.